AQUESTIVE THERAPEUTICS INC
AQSTNASDAQTrading Snapshot
- Day Range
- $3.42 β $3.65
- 52-Week Range
- $2.93 β $6.74
- Volume (shares)
- 3,360,585
- Avg Volume (shares)
- β
- Shares Outstanding
- 125.7M
- Next Earnings
- 2027-03-03
Fundamentals Snapshot
- Annual Revenue
- $45M
- Last Q Revenue
- $8M
- P/E Ratio
- -5.4
- P/S Ratio
- 8.9x
- EPS (TTM)
- $-0.63
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +33.7%
AQUESTIVE THERAPEUTICS INC
AQSTAbout AQUESTIVE THERAPEUTICS INC
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference
WARREN, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' live

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision
Aquestive Therapeutics NASDAQ: AQST is preparing for a potential U.S. launch of its needle-free treatment for severe allergic reactions, with an FDA decision expected on March 16, 2027, CEO Dan Barber said at the 2026 Je

Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference
WARREN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' live

Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting
WARREN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (βAquestiveβ or the βCompanyβ), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' liv

Traders Purchase Large Volume of Put Options on Aquestive Therapeutics (NASDAQ:AQST)
Aquestive Therapeutics, Inc. (NASDAQ: AQST - Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders purchased 6,009 put options on the company. This is an increase of approx

Aquestive Therapeutics, Inc. (AQST) Q3 2026 Earnings Call Transcript
Aquestive Therapeutics, Inc. ( AQST ) Q3 2026 Earnings Call November 4, 2026 8:00 AM EST Company Participants Faith Pomeroy-Ward Daniel Barber - CEO, President & Director Ernie Toth - Senior VP & CFO Sherry Korczynski -